Search Results - "Grzybowski, M.M."

717TiP An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors by Dudek, M.A., Zasłona, Z., Błaszczyk, R., Grzybowski, M.M., Rejczak, T., Cabaj, A., Dera, P., Lisiecki, K., Iwanowski, P., Charitos, T., Fung, S.

Get full text

1689P OATD-02 validates the benefits of pharmacological inhibition of arginase 1 and 2 in cancer by Grzybowski, M.M., Blaszczyk, R., Pomper, P., Stanczak, P.S., Borek, B., Gzik, A., Nowicka, J., Jędrzejczak, K., Rejczak, T., Mlącki, M., Guner-Chalimoniuk, N.C., Kikulska, A., Olczak, J., Pęczkowicz-Szyszka, J., Dzwonek, K., Dobrzanski, P., Gołębiowski, A., Zasłona, Z.

Get full text

Targeting ARG2 as a novel therapeutic approach for cancer by Grzybowski, M.M., Pęczkowicz-Szyszka, J., Wolska, P., Stańczak, P.S., Welzer, M., Nikolaev, E., Siwińska, A.M., Błaszczyk, R., Borek, B., Dzięgielewski, M., Gzik, A., Nowicka, J., Brzezińska, J., Jędrzejczak, K., Chrzanowski, J., Gołębiowski, A., Olczak, J., Dzwonek, K., Dobrzański, P.

Get full text

Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy by Stanczak, P.S., Grzybowski, M.M., Wolska, P., Zdziarska, A.M., Mazurkiewicz, M., Blaszczyk, R., Nowicka, J., Sosnowska, A., Ramji, K., Nowis, D., Golab, J., Golebiowski, A., Dobrzanski, P., Dzwonek, K.

Get full text

Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy by Stanczak, P.S., Grzybowski, M.M., Wolska, P., Zdziarska, A.M., Mazurkiewicz, M., Blaszczyk, R., Nowicka, J., Sosnowska, A., Ramji, K., Nowis, D., Golab, J., Golebiowski, A., Dobrzanski, P., Dzwonek, K.

Get full text

Novel dual arginase 1/2 inhibitor OATD-02 (OAT-1746) improves the efficacy of immune checkpoint inhibitors by Grzybowski, M.M., Stańczak, P.S., Pęczkowicz-Szyszka, J., Wolska, P., Zdziarska, A.M., Mazurkiewicz, M., Brzezińska, J., Blaszczyk, R., Gołębiowski, A., Dobrzański, P., Dzwonek, K.

Get full text

1973P - Targeting ARG2 as a novel therapeutic approach for cancer by Grzybowski, M.M., Pęczkowicz-Szyszka, J., Wolska, P., Stańczak, P.S., Welzer, M., Nikolaev, E., Siwińska, A.M., Błaszczyk, R., Borek, B., Dzięgielewski, M., Gzik, A., Nowicka, J., Brzezińska, J., Jędrzejczak, K., Chrzanowski, J., Gołębiowski, A., Olczak, J., Dzwonek, K., Dobrzański, P.

“…Immunotherapies are considered the most promising therapeutic approach for cancer and the immunosuppressive activity of ARG1 has been recognized as an…”
Get full text